Experimental mRNA CAR-T therapy targets autoimmune diseases in first human trial
Disease control
Recruiting now
This early-phase trial tests Arnovie101, an mRNA-based CAR-T therapy given directly into the bloodstream, in 5 people with lupus or autoimmune hemolytic anemia. The goal is to see if it is safe and how the body processes it. Researchers will also check if it reduces disease activ…
Phase: EARLY_PHASE1 • Sponsor: Circunited BioPharma (Shenzhen) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC